Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 6/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347208 | 0.89 | TP53 (0.47) | KCNH2FAAHMGLLTP53POLB | |
| SCHEMBL18347234 | 0.88 | MAPT (0.42) | KCNH2FAAHMGLLTP53MAPT | |
| SCHEMBL18347224 | 0.88 | HTR2A (0.44) | FAAHMGLLMAPTKMT2APPARA | |
| SCHEMBL18347228 | 0.87 | MAPK14 (0.49) | KCNA3KCNH2TP53KMT2APPARA | |
| SCHEMBL18347223 | 0.84 | THRA (0.47) | MAPTKMT2APPARA | |
| SCHEMBL18347245 | 0.83 | KCNH2 (0.52) | KCNH2POLBMAPTKMT2A | |
| SCHEMBL18347221 | 0.82 | KCNA3 (0.47) | KCNA3 | |
| SCHEMBL18347214 | 0.80 | MAPT (0.48) | TP53POLBMAPTKMT2APPARA | |
| SCHEMBL18347222 | 0.79 | PDE1A (0.47) | POLB | |
| SCHEMBL2174711 | 0.78 | MAPK14 (0.52) | KCNA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376235-A1 | Pyridone FabI Inhibitors and Uses Thereof | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376235-A1 | Pyridone FabI Inhibitors and Uses Thereof | PLPBP, PDXK, FBP1 | KCNA3 3748/4885KCNH2 3946/4885FAAH 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.